Linda J. Burns, MD, on CAR T-Cell Therapy in ALL
2014 ASH Annual Meeting2014 ASH President Linda J. Burns, MD, of the University of Minnesota, offers her thoughts on abstract 380, “T Cells Engineered With a Chimeric Antigen Receptor (CAR) Targeting CD19 (CTL019) Have Long-Term Persistence and Induce Durable Remissions in Children with Relapsed, Refractory ALL,” presented by Stephan A. Grupp, MD, PhD.
Time: 1:26
Related Videos
Julie M. Vose, MD, MBA, FASCO, on the AETHERA trial
Julie M. Vose, MD, MBA, FASCO, of the University of Nebraska Medical Center, offers her thoughts on abstract 673,
Richard M. Stone, MD, of Dana-Farber Cancer Institute, offers his thoughts on abstract 6,
Richard M. Stone, MD, on the SAL-SORAML Trial
Laurie Sehn, MD, on Nivolumab in Patients With Relapsed/Refractory Hodgkin Lymphoma
Laurie Sehn, MD, of the BC Cancer Agency, on abstract 289, “Nivolumab in Patients With Relapsed...
Laurie Sehn, MD, on Radiotherapy in Limited-Stage Diffuse Large B-Cell Lymphoma
Laurie Sehn, MD, of the BC Cancer Agency, on abstract 393, “R-CHOP With or Without Radiotherapy...
Hagop Kantarjian, MD, on Treating Philadelphia Chromosome–Positive ALL
Hagop Kantarjian, MD, of The University of Texas MD Anderson Cancer Center, offers his thoughts on abstract 797,
